Cargando…
Review of Transporter Substrate, Inhibitor, and Inducer Characteristics of Cladribine
Cladribine is a nucleoside analog that is phosphorylated in its target cells (B- and T-lymphocytes) to its active adenosine triphosphate form (2-chlorodeoxyadenosine triphosphate). Cladribine tablets 10 mg (Mavenclad(®)) administered for up to 10 days per year in 2 consecutive years (3.5-mg/kg cumul...
Autores principales: | Hermann, Robert, Krajcsi, Peter, Fluck, Markus, Seithel-Keuth, Annick, Bytyqi, Afrim, Galazka, Andrew, Munafo, Alain |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613159/ https://www.ncbi.nlm.nih.gov/pubmed/34435310 http://dx.doi.org/10.1007/s40262-021-01065-3 |
Ejemplares similares
-
Cladribine as a Potential Object of Nucleoside Transporter-Based Drug Interactions
por: Hermann, Robert, et al.
Publicado: (2021) -
The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis
por: Hermann, Robert, et al.
Publicado: (2018) -
Effects of cladribine tablets on heart rate, atrio‐ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis
por: Hermann, Robert, et al.
Publicado: (2019) -
Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis
por: Savic, Radojka M., et al.
Publicado: (2017) -
COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update
por: Jack, Dominic, et al.
Publicado: (2021)